{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T04:29:44Z","timestamp":1764131384644},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"S5","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1752-0509-7-s5-s5","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T12:04:43Z","timestamp":1386590683000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database"],"prefix":"10.1186","volume":"7","author":[{"given":"Chifeng","family":"Ma","sequence":"first","affiliation":[]},{"given":"Hung-I Harry","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Mario","family":"Flores","sequence":"additional","affiliation":[]},{"given":"Yufei","family":"Huang","sequence":"additional","affiliation":[]},{"given":"Yidong","family":"Chen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,12,9]]},"reference":[{"issue":"8","key":"1215_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 2009, 360 (8): 790-800. 10.1056\/NEJMra0801289.","journal-title":"N Engl J Med"},{"issue":"10","key":"1215_CR2","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1535-7163.MCT-08-0642","volume":"7","author":"RF Riedel","year":"2008","unstructured":"Riedel RF, et al: A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther. 2008, 7 (10): 3141-9. 10.1158\/1535-7163.MCT-08-0642.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1215_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/CIRCULATIONAHA.108.824177","volume":"120","author":"PJ Schlueter","year":"2009","unstructured":"Schlueter PJ, Peterson RT: Systematizing serendipity for cardiovascular drug discovery. Circulation. 2009, 120 (3): 255-63. 10.1161\/CIRCULATIONAHA.108.824177.","journal-title":"Circulation"},{"issue":"9","key":"1215_CR4","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1158\/0008-5472.CAN-08-3403","volume":"69","author":"H Ebi","year":"2009","unstructured":"Ebi H, et al: Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. Cancer Res. 2009, 69 (9): 4027-35. 10.1158\/0008-5472.CAN-08-3403.","journal-title":"Cancer Res"},{"issue":"4","key":"1215_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-08-3836","volume":"69","author":"WN Hait","year":"2009","unstructured":"Hait WN, Hambley TW: Targeted cancer therapeutics. Cancer Res. 2009, 69 (4): 1263-7. 10.1158\/0008-5472.CAN-08-3836. discussion 1267","journal-title":"Cancer Res"},{"issue":"49","key":"1215_CR6","doi-asserted-by":"publisher","first-page":"19432","DOI":"10.1073\/pnas.0806674105","volume":"105","author":"KS Garman","year":"2008","unstructured":"Garman KS, et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA. 2008, 105 (49): 19432-7. 10.1073\/pnas.0806674105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1215_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-07-6013","volume":"68","author":"T Yamashita","year":"2008","unstructured":"Yamashita T, et al: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008, 68 (5): 1451-61. 10.1158\/0008-5472.CAN-07-6013.","journal-title":"Cancer Res"},{"issue":"4","key":"1215_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1078-0432.CCR-06-1025","volume":"13","author":"HL Jia","year":"2007","unstructured":"Jia HL, et al: Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007, 13 (4): 1133-9. 10.1158\/1078-0432.CCR-06-1025.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1215_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccr.2006.06.016","volume":"10","author":"A Budhu","year":"2006","unstructured":"Budhu A, et al: prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006, 10 (2): 99-111. 10.1016\/j.ccr.2006.06.016.","journal-title":"Cancer Cell"},{"issue":"4","key":"1215_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nm843","volume":"9","author":"QH Ye","year":"2003","unstructured":"Ye QH, et al: predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003, 9 (4): 416-23. 10.1038\/nm843.","journal-title":"Nat Med"},{"key":"1215_CR11","volume-title":"Large Scale Genome Variation in Health and Disease in: Cytogenetics and Genome Research","author":"AGV Kessel","year":"2006","unstructured":"Kessel AGV: Large Scale Genome Variation in Health and Disease in: Cytogenetics and Genome Research. Edited by: Nijmegen. 2006"},{"issue":"1","key":"1215_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nrc2044","volume":"7","author":"J Lamb","year":"2007","unstructured":"Lamb J: The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer. 2007, 7 (1): 54-60. 10.1038\/nrc2044.","journal-title":"Nat Rev Cancer"},{"issue":"32","key":"1215_CR13","doi-asserted-by":"publisher","first-page":"13086","DOI":"10.1073\/pnas.0610292104","volume":"104","author":"JK Lee","year":"2007","unstructured":"Lee JK, et al: A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA. 2007, 104 (32): 13086-91. 10.1073\/pnas.0610292104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"43","key":"1215_CR14","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102 (43): 15545-50. 10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1215_CR15","doi-asserted-by":"publisher","first-page":"e22274","DOI":"10.1371\/journal.pone.0022274","volume":"6","author":"L Huang","year":"2011","unstructured":"Huang L, et al: An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One. 2011, 6 (7): e22274-10.1371\/journal.pone.0022274.","journal-title":"PLoS One"},{"key":"1215_CR16","first-page":"513","volume-title":"Mol Syst Biol","author":"AL Cohen","year":"2011","unstructured":"Cohen AL, et al: A pharmacogenomic method for individualized prediction of drug sensitivity. Mol Syst Biol. 2011, 513-"},{"issue":"11","key":"1215_CR17","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.201207-1180OC","volume":"186","author":"CT Yeh","year":"2012","unstructured":"Yeh CT, et al: Trifluoperazine an antipsychotic agent inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012, 186 (11): 1180-8. 10.1164\/rccm.201207-1180OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1215_CR18","doi-asserted-by":"publisher","first-page":"e54211","DOI":"10.1371\/journal.pone.0054211","volume":"8","author":"HF Yuen","year":"2013","unstructured":"Yuen HF, et al: TAZ Expression as a Prognostic Indicator in Colorectal Cancer. PLoS One. 2013, 8 (1): e54211-10.1371\/journal.pone.0054211.","journal-title":"PLoS One"},{"key":"1215_CR19","first-page":"805614","volume-title":"Sarcoma","author":"B Edris","year":"2012","unstructured":"Edris B, et al: Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma. 2012, 805614-"},{"issue":"11","key":"1215_CR20","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1097\/JTO.0b013e31822adfb0","volume":"6","author":"AK Reka","year":"2011","unstructured":"Reka AK, et al: Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol. 2011, 6 (11): 1784-92. 10.1097\/JTO.0b013e31822adfb0.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1215_CR21","doi-asserted-by":"publisher","first-page":"e24662","DOI":"10.1371\/journal.pone.0024662","volume":"6","author":"S Claerhout","year":"2011","unstructured":"Claerhout S, et al: Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One. 2011, 6 (9): e24662-10.1371\/journal.pone.0024662.","journal-title":"PLoS One"},{"issue":"9","key":"1215_CR22","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1158\/1535-7163.MCT-09-0966","volume":"9","author":"MY Lan","year":"2010","unstructured":"Lan MY, et al: From NPC therapeutic target identification to potential treatment strategy. Mol Cancer Ther. 2010, 9 (9): 2511-23. 10.1158\/1535-7163.MCT-09-0966.","journal-title":"Mol Cancer Ther"},{"key":"1215_CR23","first-page":"80","volume-title":"BMC Syst Biol","author":"HS Lee","year":"2012","unstructured":"Lee HS, et al: Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol. 2012, 80-"},{"key":"1215_CR24","first-page":"496","volume-title":"Mol Syst Biol","author":"A Gottlieb","year":"2011","unstructured":"Gottlieb A, et al: pREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol. 2011, 496-"},{"issue":"8","key":"1215_CR25","doi-asserted-by":"publisher","first-page":"e6536","DOI":"10.1371\/journal.pone.0006536","volume":"4","author":"G Hu","year":"2009","unstructured":"Hu G, Agarwal P: Human disease-drug network based on genomic expression profiles. PLoS One. 2009, 4 (8): e6536-10.1371\/journal.pone.0006536.","journal-title":"PLoS One"},{"issue":"5","key":"1215_CR26","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1158\/0008-5472.CAN-10-1735","volume":"71","author":"I Shats","year":"2011","unstructured":"Shats I, et al: Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011, 71 (5): 1772-80. 10.1158\/0008-5472.CAN-10-1735.","journal-title":"Cancer Res"},{"issue":"1","key":"1215_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/0008-5472.CAN-11-2333","volume":"72","author":"G Jin","year":"2012","unstructured":"Jin G, et al: A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res. 2012, 72 (1): 33-44. 10.1158\/0008-5472.CAN-11-2333.","journal-title":"Cancer Res"},{"issue":"14","key":"1215_CR28","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/bioinformatics\/bts290","volume":"28","author":"C Zhao","year":"2012","unstructured":"Zhao C, et al: Identifying mechanistic similarities in drug responses. Bioinformatics. 2012, 28 (14): 1902-10. 10.1093\/bioinformatics\/bts290.","journal-title":"Bioinformatics"},{"issue":"2","key":"1215_CR29","doi-asserted-by":"publisher","first-page":"e1002347","DOI":"10.1371\/journal.pcbi.1002347","volume":"8","author":"D Shigemizu","year":"2012","unstructured":"Shigemizu D, et al: Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012, 8 (2): e1002347-10.1371\/journal.pcbi.1002347.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"1215_CR30","doi-asserted-by":"publisher","first-page":"e16382","DOI":"10.1371\/journal.pone.0016382","volume":"6","author":"DG McArt","year":"2011","unstructured":"McArt DG, Zhang SD: Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. PLoS One. 2011, 6 (1): e16382-10.1371\/journal.pone.0016382.","journal-title":"PLoS One"},{"issue":"20","key":"1215_CR31","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1093\/bioinformatics\/bts502","volume":"28","author":"H Ma","year":"2012","unstructured":"Ma H, Zhao H: FacPad: Bayesian sparse factor modeling for the inference of pathways responsive to drug treatment. Bioinformatics. 2012, 28 (20): 2662-70. 10.1093\/bioinformatics\/bts502.","journal-title":"Bioinformatics"},{"issue":"1","key":"1215_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/iub.279","volume":"62","author":"P Bulzomi","year":"2010","unstructured":"Bulzomi P, et al: Naringenin and 17beta-estradiol coadministration prevents hormone-induced human cancer cell growth. IUBMB Life. 2010, 62 (1): 51-60.","journal-title":"IUBMB Life"},{"issue":"3","key":"1215_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1677\/jme.0.0320649","volume":"32","author":"A Inoue","year":"2004","unstructured":"Inoue A, et al: Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol. 2004, 32 (3): 649-61. 10.1677\/jme.0.0320649.","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"1215_CR34","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1186\/bcr2614","volume":"12","author":"Y Drabsch","year":"2010","unstructured":"Drabsch Y, Robert RG, Gonda TJ: MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 2010, 12 (4): R55-10.1186\/bcr2614.","journal-title":"Breast Cancer Res"},{"issue":"14","key":"1215_CR35","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1158\/0008-5472.CAN-05-4269","volume":"66","author":"J Frasor","year":"2006","unstructured":"Frasor J, et al: Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006, 66 (14): 7334-40. 10.1158\/0008-5472.CAN-05-4269.","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"1215_CR36","doi-asserted-by":"publisher","first-page":"561S","DOI":"10.1002\/j.1550-8528.1995.tb00228.x","volume":"3","author":"FL Greenway","year":"1995","unstructured":"Greenway FL, Bray GA, Heber D: Topical fat reduction. Obes Res. 1995, 3 (Suppl 4): 561S-568S.","journal-title":"Obes Res"},{"key":"1215_CR37","first-page":"10","volume-title":"Chin Med","author":"AJ Guo","year":"2012","unstructured":"Guo AJ, et al: Kaempferol as a flavonoid induces osteoblastic differentiation via estrogen receptor signaling. Chin Med. 2012, 10-"},{"issue":"4","key":"1215_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.febslet.2009.01.030","volume":"583","author":"J Wang","year":"2009","unstructured":"Wang J, et al: Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist. FEBS Lett. 2009, 583 (4): 643-7. 10.1016\/j.febslet.2009.01.030.","journal-title":"FEBS Lett"},{"issue":"2","key":"1215_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jcp.10398","volume":"198","author":"H Hung","year":"2004","unstructured":"Hung H: Inhibition of estrogen receptor alpha expression and function in MCF-7 cells by kaempferol. Journal of Cellular Physiology. 2004, 198 (2): 197-208. 10.1002\/jcp.10398.","journal-title":"Journal of Cellular Physiology"},{"issue":"3","key":"1215_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1677\/JOE-07-0358","volume":"195","author":"HJ Kim","year":"2007","unstructured":"Kim HJ, et al: Estrogen receptor alpha-induced cholecystokinin type A receptor expression in the female mouse pituitary. J Endocrinol. 2007, 195 (3): 393-405. 10.1677\/JOE-07-0358.","journal-title":"J Endocrinol"},{"issue":"7","key":"1215_CR41","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/CAD.0b013e3280a02f2b","volume":"18","author":"MD Planas-Silva","year":"2007","unstructured":"Planas-Silva MD, Filatova IS: Estrogen-dependent regulation of Eg5 in breast cancer cells. Anticancer Drugs. 2007, 18 (7): 773-9. 10.1097\/CAD.0b013e3280a02f2b.","journal-title":"Anticancer Drugs"},{"key":"1215_CR42","volume-title":"Contemporary issues in clinical biochemistry","author":"B Widdop","year":"1985","unstructured":"Widdop B: Therapeutic drug monitoring. Contemporary issues in clinical biochemistry. 1985, Edinburgh; New York: Churchill Livingstone"},{"issue":"3","key":"1215_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0277-5379(98)90011-6","volume":"24","author":"PH Willemse","year":"1988","unstructured":"Willemse PH, et al: Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol. 1988, 24 (3): 417-21. 10.1016\/S0277-5379(98)90011-6.","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"12","key":"1215_CR44","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1158\/1535-7163.MCT-12-0447","volume":"11","author":"N Awasthi","year":"2012","unstructured":"Awasthi N, et al: BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor\/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther. 2012, 11 (12): 2644-53. 10.1158\/1535-7163.MCT-12-0447.","journal-title":"Mol Cancer Ther"},{"key":"1215_CR45","volume-title":"Invest New Drugs","author":"SJ Lee","year":"2012","unstructured":"Lee SJ, et al: A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography. Invest New Drugs. 2012"},{"issue":"4","key":"1215_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/pbc.22741","volume":"56","author":"EA Kolb","year":"2011","unstructured":"Kolb EA, et al: Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011, 56 (4): 595-603. 10.1002\/pbc.22741.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"1215_CR47","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1158\/1535-7163.MCT-09-0499","volume":"8","author":"JM Carboni","year":"2009","unstructured":"Carboni JM, et al: BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R\/IR. Mol Cancer Ther. 2009, 8 (12): 3341-9. 10.1158\/1535-7163.MCT-09-0499.","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"1215_CR48","first-page":"581s","volume":"69","author":"BC Litzenburger","year":"2009","unstructured":"Litzenburger BC, et al: High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines Correlates with Sensitivity to IGF-IR Inhibitor BMS-754807 in This Subtype of Human Breast Cancer. Cancer Research. 2009, 69 (24): 581s-581s.","journal-title":"Cancer Research"},{"key":"1215_CR49","first-page":"111","volume-title":"Annals of Oncology","author":"Y Tamura","year":"2012","unstructured":"Tamura Y, et al: phase 1 Dose-Escalating Study of Bms-754807 in Japanese Patients with Advanced Solid Tumors. Annals of Oncology. 2012, 111-112."},{"issue":"4","key":"1215_CR50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/pbc.22741","volume":"56","author":"EA Kolb","year":"2011","unstructured":"Kolb EA, et al: Initial Testing (Stage 1) of the IGF-1 Receptor Inhibitor BMS-754807 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2011, 56 (4): 595-603. 10.1002\/pbc.22741.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"1215_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1359-6349(10)72119-4","volume":"8","author":"QS Chu","year":"2010","unstructured":"Chu QS, et al: BMS-754807, an oral dual IGF-1R\/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin\/paclitaxel in subjects with solid tumors. Ejc Supplements. 2010, 8 (7): 131-131.","journal-title":"Ejc Supplements"},{"key":"1215_CR52","first-page":"9","volume-title":"Annals of Oncology","author":"J Desai","year":"2010","unstructured":"Desai J, et al: Targeting Type I Insulin-Like Growth Factor Receptor and Insulin Receptor for Cancer Therapy: The Oral Dual Inhibitor Bms-754807 in Clinical Development. Annals of Oncology. 2010, 9-9."},{"key":"1215_CR53","first-page":"254","volume-title":"Trans Am Neurol Assoc","author":"RL Macdonald","year":"1978","unstructured":"Macdonald RL, Bergey GK: Valproic acid: effect on GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons. Trans Am Neurol Assoc. 1978, 254-6."},{"issue":"3","key":"1215_CR54","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez A, et al: Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008, 34 (3): 206-22. 10.1016\/j.ctrv.2007.11.003.","journal-title":"Cancer Treat Rev"},{"issue":"33","key":"1215_CR55","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.2174\/138161207782360528","volume":"13","author":"M Michaelis","year":"2007","unstructured":"Michaelis M, Doerr HW, Cinatl J: Valproic acid as anti-cancer drug. Curr Pharm Des. 2007, 13 (33): 3378-93. 10.2174\/138161207782360528.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"1215_CR56","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2007.10.006","volume":"259","author":"N Fortunati","year":"2008","unstructured":"Fortunati N, et al: Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett. 2008, 259 (2): 156-64. 10.1016\/j.canlet.2007.10.006.","journal-title":"Cancer Lett"},{"issue":"11","key":"1215_CR57","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1200\/JCO.2005.03.2755","volume":"24","author":"DS Oh","year":"2006","unstructured":"Oh DS, et al: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. Journal of Clinical Oncology. 2006, 24 (11): 1656-64. 10.1200\/JCO.2005.03.2755.","journal-title":"Journal of Clinical Oncology"},{"key":"1215_CR58","volume-title":"Dictionary of pharmacological agents","author":"F Macdonald","year":"1997","unstructured":"Macdonald F: Dictionary of pharmacological agents. 1997, London; Weinheim; New York: Chapman & Hall, 1 livret d'installation d'un c\u00e9d\u00e9rom"},{"issue":"8","key":"1215_CR59","first-page":"2228","volume":"7","author":"PN Munster","year":"2001","unstructured":"Munster PN, et al: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin, sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin Cancer Res. 2001, 7 (8): 2228-36.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1215_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nchem.1596","volume":"5","author":"RR Kitson","year":"2013","unstructured":"Kitson RR, et al: Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem. 2013, 5 (4): 307-14. 10.1038\/nchem.1596.","journal-title":"Nat Chem"},{"issue":"2","key":"1215_CR61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jmb.2007.06.065","volume":"372","author":"SC Onuoha","year":"2007","unstructured":"Onuoha SC, et al: Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol. 2007, 372 (2): 287-97. 10.1016\/j.jmb.2007.06.065.","journal-title":"J Mol Biol"},{"issue":"4","key":"1215_CR62","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3892\/ijo.2012.1551","volume":"41","author":"D Bellarosa","year":"2012","unstructured":"Bellarosa D, et al: SAHA\/Vorinostat induces the expression of the CD137 receptor\/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol. 2012, 41 (4): 1486-1494.","journal-title":"Int J Oncol"},{"issue":"2","key":"1215_CR63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-012-2171-9","volume":"135","author":"W Fiskus","year":"2012","unstructured":"Fiskus W, et al: Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Research and Treatment. 2012, 135 (2): 433-444. 10.1007\/s10549-012-2171-9.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"1215_CR64","first-page":"105","volume":"28","author":"N Uehara","year":"2012","unstructured":"Uehara N, Yoshizawa K, Tsubura A: Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells. Oncology Reports. 2012, 28 (1): 105-110.","journal-title":"Oncology Reports"},{"issue":"2","key":"1215_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2011.07.032","volume":"315","author":"N Uehara","year":"2012","unstructured":"Uehara N, et al: Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Cancer Lett. 2012, 315 (2): 112-121. 10.1016\/j.canlet.2011.07.032.","journal-title":"Cancer Lett"},{"issue":"11","key":"1215_CR66","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/FPC.0b013e32834a8639","volume":"21","author":"NS Wong","year":"2011","unstructured":"Wong NS, et al: Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet Genomics. 2011, 21 (11): 760-768. 10.1097\/FPC.0b013e32834a8639.","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"1215_CR67","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/bjc.2011.156","volume":"104","author":"PN Munster","year":"2011","unstructured":"Munster PN, et al: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011, 104 (12): 1828-1835. 10.1038\/bjc.2011.156.","journal-title":"Br J Cancer"},{"issue":"5","key":"1215_CR68","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pmic.200900602","volume":"10","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, et al: Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics. 2010, 10 (5): 1029-1039.","journal-title":"Proteomics"},{"issue":"24","key":"1215_CR69","first-page":"793s","volume":"69","author":"RF Swaby","year":"2009","unstructured":"Swaby RF, et al: A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and\/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. Cancer Research. 2009, 69 (24): 793s-793s.","journal-title":"Cancer Research"},{"issue":"7","key":"1215_CR70","first-page":"905","volume":"26","author":"D Palmieri","year":"2009","unstructured":"Palmieri D, et al: preclinical studies in support of the use of vorinostat (SAHA) for the treatment of brain metastases of breast cancer. Clinical & Experimental Metastasis. 2009, 26 (7): 905-906.","journal-title":"Clinical & Experimental Metastasis"},{"key":"1215_CR71","doi-asserted-by":"crossref","unstructured":"Munster PN: phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. Journal of Clinical Oncology. 2009, 27 (15):","DOI":"10.1200\/jco.2009.27.15_suppl.1075"},{"issue":"1","key":"1215_CR72","first-page":"416","volume":"15","author":"TH Luu","year":"2009","unstructured":"Luu TH, Morgan RJ, Leong L: A Phase II Trial of Vorinostat in Metastatic Breast Cancer (vol 14, pg 7138, 2008). Clinical Cancer Research. 2009, 15 (1): 416-416.","journal-title":"Clinical Cancer Research"},{"issue":"21","key":"1215_CR73","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","volume":"14","author":"TH Luu","year":"2008","unstructured":"Luu TH, et al: A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study. Clinical Cancer Research. 2008, 14 (21): 7138-7142. 10.1158\/1078-0432.CCR-08-0122.","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"1215_CR74","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2174\/0929867043365099","volume":"11","author":"T Vanhaecke","year":"2004","unstructured":"Vanhaecke T, et al: Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Current Medicinal Chemistry. 2004, 11 (12): 1629-43. 10.2174\/0929867043365099.","journal-title":"Current Medicinal Chemistry"},{"issue":"1","key":"1215_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s13277-012-0544-7","volume":"34","author":"M Tavakoli-Yaraki","year":"2013","unstructured":"Tavakoli-Yaraki M, et al: Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1. Tumour Biol. 2013, 34 (1): 241-9. 10.1007\/s13277-012-0544-7.","journal-title":"Tumour Biol"},{"issue":"1","key":"1215_CR76","first-page":"143","volume":"22","author":"S Nakajima","year":"2009","unstructured":"Nakajima S, et al: Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231. Oncology Reports. 2009, 22 (1): 143-8.","journal-title":"Oncology Reports"},{"key":"1215_CR77","first-page":"8","volume-title":"Mol Cancer","author":"JP Alao","year":"2006","unstructured":"Alao JP, et al: Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer. 2006, 8-"},{"issue":"5","key":"1215_CR78","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/BF02980131","volume":"27","author":"KN Min","year":"2004","unstructured":"Min KN, et al: Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells. Arch Pharm Res. 2004, 27 (5): 554-61. 10.1007\/BF02980131.","journal-title":"Arch Pharm Res"},{"issue":"4","key":"1215_CR79","first-page":"971","volume":"7","author":"DM Vigushin","year":"2001","unstructured":"Vigushin DM, et al: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001, 7 (4): 971-6.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-0509-7-S5-S5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T06:44:59Z","timestamp":1716273899000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/1752-0509-7-S5-S5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":79,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1186\/1752-0509-7-s5-s5","relation":{},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"9 December 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S5"}}